Angiotensin I-converting enzyme inhibitors/angiotensin II receptor blockers may reduce tumor recurrence in left-sided and early colorectal cancers.
Aged
Angiotensin Receptor Antagonists
/ therapeutic use
Angiotensin-Converting Enzyme Inhibitors
/ therapeutic use
Cohort Studies
Colon
/ pathology
Colorectal Neoplasms
/ drug therapy
Databases as Topic
Disease-Free Survival
Female
Humans
Male
Multivariate Analysis
Neoplasm Recurrence, Local
/ drug therapy
Proportional Hazards Models
Up-Regulation
AGTR1
Angiotensin
Angiotensin I-converting enzyme inhibitor (ACEI)
Angiotensin II receptor blocker (ARB)
Colorectal cancer (CRC)
Recurrence
Journal
International journal of colorectal disease
ISSN: 1432-1262
Titre abrégé: Int J Colorectal Dis
Pays: Germany
ID NLM: 8607899
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
accepted:
23
08
2019
pubmed:
4
9
2019
medline:
6
2
2020
entrez:
4
9
2019
Statut:
ppublish
Résumé
Angiotensin signaling is suggested to be involved in tumorigenesis, tumor proliferation, and metastases. In colorectal cancer (CRC), it was demonstrated that angiotensin I-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) may reduce the risk of CRC; however, their impact on tumor recurrence remains unknown. Therefore, in this study, we evaluated the impact of ACEIs/ARBs on tumor recurrence in CRC patients. We retrospectively investigated the clinicopathological data of 461 stage I-III CRC patients. We divided the patients into those who took an ACEI and/or ARB (the ACEI/ARB+ group) and those who did not (the ACEI/ARB- group), and we compared the two groups' recurrence-free survival (RFS) using a Kaplan-Meier curve analysis and log rank test. We also examined the impact of AGTR1 expression on tumor recurrence, using two public CRC datasets. The Kaplan-Meier curves showed a trend toward improved RFS in the ACEI/ARB+ group versus the ACEI/ARB- group (p = 0.063). Subgroup analyses demonstrated that the RFS was significantly better in the ACEI/ARB+ group versus the ACEI/ARB- group in the patients with left-sided CRC (p = 0.030) and those with stage I CRC (p = 0.009). Consistent with these findings, the AGTR1 expression was higher in the left-sided versus right-sided colon (p = 0.048). High AGTR1 expression levels were associated with poor RFS in the GSE39582 dataset's stage I-III CRC patients (p < 0.001), and this finding was also validated in the GSE17536 dataset (p = 0.023). ACEI/ARB treatment may reduce tumor recurrence in left-sided CRC and early-stage CRC.
Sections du résumé
BACKGROUND
BACKGROUND
Angiotensin signaling is suggested to be involved in tumorigenesis, tumor proliferation, and metastases. In colorectal cancer (CRC), it was demonstrated that angiotensin I-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) may reduce the risk of CRC; however, their impact on tumor recurrence remains unknown. Therefore, in this study, we evaluated the impact of ACEIs/ARBs on tumor recurrence in CRC patients.
PATIENTS AND METHODS
METHODS
We retrospectively investigated the clinicopathological data of 461 stage I-III CRC patients. We divided the patients into those who took an ACEI and/or ARB (the ACEI/ARB+ group) and those who did not (the ACEI/ARB- group), and we compared the two groups' recurrence-free survival (RFS) using a Kaplan-Meier curve analysis and log rank test. We also examined the impact of AGTR1 expression on tumor recurrence, using two public CRC datasets.
RESULTS
RESULTS
The Kaplan-Meier curves showed a trend toward improved RFS in the ACEI/ARB+ group versus the ACEI/ARB- group (p = 0.063). Subgroup analyses demonstrated that the RFS was significantly better in the ACEI/ARB+ group versus the ACEI/ARB- group in the patients with left-sided CRC (p = 0.030) and those with stage I CRC (p = 0.009). Consistent with these findings, the AGTR1 expression was higher in the left-sided versus right-sided colon (p = 0.048). High AGTR1 expression levels were associated with poor RFS in the GSE39582 dataset's stage I-III CRC patients (p < 0.001), and this finding was also validated in the GSE17536 dataset (p = 0.023).
CONCLUSION
CONCLUSIONS
ACEI/ARB treatment may reduce tumor recurrence in left-sided CRC and early-stage CRC.
Identifiants
pubmed: 31478086
doi: 10.1007/s00384-019-03379-y
pii: 10.1007/s00384-019-03379-y
doi:
Substances chimiques
Angiotensin Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1731-1739Références
Am J Gastroenterol. 2000 Oct;95(10):2953-7
pubmed: 11051374
Biochem Biophys Res Commun. 2002 Jun 7;294(2):441-7
pubmed: 12051731
Lancet Oncol. 2004 May;5(5):292-302
pubmed: 15120666
J Clin Oncol. 2005 Feb 10;23(5):1011-27
pubmed: 15585754
J Gastroenterol Hepatol. 2007 Apr;22(4):577-84
pubmed: 17376054
Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1206-12
pubmed: 17548686
Gastroenterology. 2010 Mar;138(3):958-68
pubmed: 19914252
BMC Cancer. 2010 Apr 10;10:134
pubmed: 20380732
Br J Cancer. 2010 Nov 23;103(11):1644-8
pubmed: 20978506
Br J Cancer. 2010 Nov 23;103(11):1698-705
pubmed: 21102591
BMC Cancer. 2011 Jun 26;11:274
pubmed: 21703011
PLoS One. 2012;7(12):e50893
pubmed: 23251399
PLoS Med. 2013;10(5):e1001453
pubmed: 23700391
Br J Cancer. 2013 Jul 9;109(1):249-56
pubmed: 23778525
Cancer Epidemiol. 2013 Dec;37(6):881-5
pubmed: 24075077
Lancet. 2014 Apr 26;383(9927):1490-1502
pubmed: 24225001
J Natl Cancer Inst. 2014 Feb;106(2):djt374
pubmed: 24431411
BMC Med. 2014 Feb 13;12:28
pubmed: 24521426
J Am Soc Nephrol. 2015 Jan;26(1):107-20
pubmed: 25012166
Pathobiology. 2014;81(4):169-75
pubmed: 25138435
Gut. 2015 Sep;64(9):1419-25
pubmed: 25239119
Int J Colorectal Dis. 2015 Jun;30(6):749-52
pubmed: 25592047
Br J Cancer. 2015 Oct 20;113(8):1133-9
pubmed: 26372700
Mol Clin Oncol. 2015 Nov;3(6):1295-1300
pubmed: 26807236
JAMA Oncol. 2017 Feb 1;3(2):211-219
pubmed: 27787550
Oncotarget. 2017 Jan 10;8(2):3206-3225
pubmed: 27965461
Medicine (Baltimore). 2017 Mar;96(13):e6394
pubmed: 28353566
Cancer Sci. 2017 Sep;108(9):1757-1768
pubmed: 28660748
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Ann Surg. 2018 Jul 24;:null
pubmed: 30048321